These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs. Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022 [TBL] [Abstract][Full Text] [Related]
3. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal? Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234 [TBL] [Abstract][Full Text] [Related]
4. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome. Ferdinand KC J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. Ghiadoni L; Bruno RM; Cartoni G; Stea F; Magagna A; Virdis A; Grassi D; Ferri C; Taddei S Vascul Pharmacol; 2017 May; 92():16-21. PubMed ID: 26070528 [TBL] [Abstract][Full Text] [Related]
7. Treating essential hypertension. The first choice is usually a thiazide diuretic. Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125 [TBL] [Abstract][Full Text] [Related]
8. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Owen JG; Reisin E Curr Hypertens Rep; 2015 Jun; 17(6):558. PubMed ID: 25916862 [TBL] [Abstract][Full Text] [Related]
9. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Musini VM; Nazer M; Bassett K; Wright JM Cochrane Database Syst Rev; 2014 May; 2014(5):CD003824. PubMed ID: 24869750 [TBL] [Abstract][Full Text] [Related]
10. Heart Rate Variability in Patients with Hypertension: the Effect of Metabolic Syndrome and Antihypertensive Treatment. Maciorowska M; Krzesiński P; Wierzbowski R; Gielerak G Cardiovasc Ther; 2020; 2020():8563135. PubMed ID: 33123219 [TBL] [Abstract][Full Text] [Related]
11. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Bourebaba Y; Mularczyk M; Marycz K; Bourebaba L Biomed Pharmacother; 2021 Feb; 134():111113. PubMed ID: 33341043 [TBL] [Abstract][Full Text] [Related]
12. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Suchard MA; Schuemie MJ; Krumholz HM; You SC; Chen R; Pratt N; Reich CG; Duke J; Madigan D; Hripcsak G; Ryan PB Lancet; 2019 Nov; 394(10211):1816-1826. PubMed ID: 31668726 [TBL] [Abstract][Full Text] [Related]
19. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. Weber MA J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological interventions for hypertension in children. Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]